Materialise NV 6-K, filed May 22, 2024
Materialise NV (MTLS)
About this 6-K
Materialise NV filed this 6-K on May 22, 2024.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2024
Commission File Number: 001-36515
Materialise NV
Technologielaan 15
3001 Leuven
Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
EXHIBIT INDEX
| Exhibit | Description | |
| 99.1 | Press Release dated May 22, 2024 | |
| 99.2 | Board of Directors Annual Report (English translation)* | |
*Constitutes an unofficial English translation of the original Dutch document. The Dutch document shall govern in all respects, including interpretation matters.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MATERIALISE NV | ||
| By: | /s/ Brigitte de Vet-Veithen | |
| Name: | Brigitte de Vet-Veithen | |
| Title: | Chief Executive Officer | |
Date: May 22, 2024
Exhibit 99.1
Materialise to Hold Annual Shareholders’ Meeting on June 4, 2024
LEUVEN, Belgium, May 22, 2024 (GLOBE NEWSWIRE) -- Materialise NV (NASDAQ:MTLS), a leading provider of additive manufacturing software and sophisticated 3D printing solutions, today announced that it will host its Annual General Shareholders’ Meeting at 10:00 am CEST on Tuesday, June 4, 2024.
The convening notices and other documents pertaining to the Annual General Shareholders’ Meeting, including the annual report, are available on Materialise's website at https://investors.materialise.com/governance-documents
About
Materialise
Materialise incorporates more than three decades of 3D printing experience into a range of software solutions and 3D printing services
that empower sustainable 3D printing applications. Our open, secure, and flexible end-to-end solutions enable flexible industrial manufacturing
and mass personalization in various industries — including healthcare, automotive, aerospace, eyewear, art and design, wearables,
and consumer goods. Headquartered in Belgium and with branches worldwide, Materialise combines the largest group of software
developers in the industry with one of the world's largest and most complete 3D printing facilities. For additional information, please
visit www.materialise.com
For additional information, please visit: www.materialise.com
Kristof Sehmke
Materialise
+32477702260
kristof.sehmke@materialise.be
Exhibit 99.2
Final version – Free translation for information purposes only
Materialise NV
Technologielaan 15
3001 Leuven
Enterprise number: 0441.131.254
RPR/RPM Leuven
(the "Company" or “we”)
MANAGEMENT REPORT
TO THE ANNUAL GENERAL MEETING
TO BE HELD ON 4 JUNE 2024
Ladies and Gentlemen,
In accordance with the requirements laid down by law and the articles of association of the Company, the board of directors of the Company is pleased to report to you about the activities of the Company and its subsidiaries (the "Group") for the financial year starting on January 1, 2023 and ending on December 31, 2023, and to present to you both the statutory annual accounts as well as the consolidated annual accounts as at December 31, 2023. This report has been prepared in accordance with articles 3:5 and 3:32 of the Belgian Code of Companies and Associations. For additional information, please refer to our annual report on Form 20-F which has been filed with the SEC and is available on our website.
| 1. | Analysis of the operating results on a consolidated basis |
On a consolidated basis, the results of our operations, as derived from our consolidated annual accounts prepared in accordance with IFRS as issued by IASB and adopted by the European Union, can be summarized as follows:
Comparison of the Years Ended December 31, 2023 and 2022
| Year Ended December 31, | ||||||||||||
| 2023 | 2022 | % Change | ||||||||||
| (in thousands of €) | (%) | |||||||||||
| Revenue | 256,127 | 232,023 | 10.4 | % | ||||||||
| Cost of sales | (110,996 | ) | (103,255 | ) | 7.5 | % | ||||||
| Gross profit | 145,131 | 128,768 | 12.7 | % | ||||||||
| Research and development expenses | (38,098 | ) | (37,568 | ) | 1.4 | % | ||||||
| Sales and marketing expenses | (57,822 | ) | (62,125 | ) | (6.9 | )% | ||||||
| General and administrative expenses | (37,068 | ) | (35,143 | ) | 5.5 | % | ||||||
| Net other operating income (expenses) | (6,524 | ) | 3,196 | |||||||||
| Operating (loss) profit | 5,619 | (2,872 | ) | |||||||||
| Financial expenses | (3,865 | ) | (4,420 | ) | ||||||||
| Financial income | 5,019 | 6,114 | ||||||||||
| (Loss) profit before taxes | 6,772 | (1,178 | ) | |||||||||
| Income taxes | (78 | ) | (975 | ) | ||||||||
| Net (loss) profit for the year | 6,695 | (2,153 | ) | |||||||||
1
Final version – Free translation for information purposes only
Comparison for the Years Ended December 31, 2023 and 2022 by Segment
| Materialise Software | Materialise Medical | Materialise Manufacturing | Total
Segments | Unallocated (1) | Consolidated | |||||||||||||||||||
| (in thousands of €, except percentages) | ||||||||||||||||||||||||
| For the year ended December 31, 2023 | ||||||||||||||||||||||||
| Revenues | 44,442 | 101,376 | 110,310 | 256,127 | 256,127 | |||||||||||||||||||
| Segment Adjusted EBITDA | 7,450 | 26,544 | 7,537 | 41,530 | (10,133) | 31,397 | ||||||||||||||||||
| Segment Adjusted EBITDA % | 16.8 | % | 26.2 | % | 6.8 | % | 16.2 | % | 12.3 | % | ||||||||||||||
| For the year ended December 31, 2022 | ||||||||||||||||||||||||
| Revenues | 43,688 | 84,846 | 103,489 | 232,023 | 232,023 | |||||||||||||||||||
| Segment Adjusted EBITDA | 1,514 | 18,822 | 8,229 | 28,565 | (9,551) | 19,014 | ||||||||||||||||||
| Segment Adjusted EBITDA % | 3.5 | % | 22.2 | % | 8.0 | % | 12.3 | % | 8.2 | % | ||||||||||||||
(1) Unallocated related Segment Adjusted EBITDA consist of corporate research and development, corporate headquarter costs and other operating income (expense).
2
Final version – Free translation for information purposes only
Comparison for the Years Ended December 31, 2023 and 2022
| Year ended December 31, | ||||||||
| In 000€ | 2023 | 2022 | ||||||
| Assets | ||||||||
| Non-current assets | 190,166 | 194,847 | ||||||
| Current assets | 206,465 | 216,415 | ||||||
| Total assets | 396,630 | 411,262 | ||||||
| Equity and liabilities | ||||||||
| Equity attributable to the owners of the parent | 236,646 | 228,955 | ||||||
| Non-controlling interest | (53 | ) | (28 | ) | ||||
| Equity | 236,594 | 228,928 | ||||||
| Non-current liabilities | 55,086 | 76,220 | ||||||
| Current liabilities | 104,950 | 106,114 | ||||||
| Total equity and liabilities | 396,630 | 411,262 | ||||||
Analysis
Revenue. Revenue increased by € 24.1 million, or 10.4%, to € 256.1 million in the year ended December 31, 2023, from € 232.0 million in the year ended December 31, 2022.
Revenue from our Materialise Software segment increased € 0.7 million, or 1.7%, from € 43.7 million in the year ended December 31, 2022, to € 44.4 million in the year ended December 31, 2023. Recurrent revenue, consisting of limited license fees and maintenance fees, increased by € 2.0 million, or 7.2%, in the year ended December 31, 2023. Non-recurrent revenue, mainly consisting of perpetual fees and services, decreased by € 1.2 million, or 7.6%, in the year ended December 31, 2023. Deferred revenue from license and maintenance fees amounted to € 0.8 million in the year ended December 31, 2023, compared to € 2.7 million in the year ended December 31, 2022.
Revenue from our Materialise Medical segment increased € 16.5 million, or 19.5%, from € 84.8 million in the year ended December 31, 2022, to € 101.4 million in the year ended December 31, 2023. Within our medical software department recurrent revenue from annual and renewed licenses and maintenance fees increased by € 4.7 million, or 20.3%, reflecting the implementation of our continued strategy focused on products with defined contractual periods. These recurrent revenues represented 87.2% of all medical software revenues in the year ended December 31, 2023, compared to 84.8% in the year ended December 31, 2022. Our non-recurrent revenue from perpetual licenses and services remained consistent in the year ended December 31, 2023, compared to the year ended December 31, 2022. Deferred revenue from license and maintenance fees amounted to € 0.7 million in the year ended December 31, 2023, compared to € 5.1 million in the year ended December 31, 2022. Revenues from medical devices and services grew by € 11.9 million, or 20.6%, in the year ended December 31, 2023, driven by growth in all of our sales channels across our different core markets. As of December 31, 2023, our Materialise Medical segment operated 50 3D printers, as compared to 49 as of December 31, 2022.
3
Final version – Free translation for information purposes only
Revenue from our Materialise Manufacturing segment increased € 6.8 million, or 6.6%, from € 103.5 million in the year ended December 31, 2022, to € 110.3 million in the year ended December 31, 2023. Materialise Manufacturing operated 157 3D printers, 28 CNC machines and 5 vacuum casting machines as of December 31, 2023, compared to 156 3D printers, 22 CNC machines and 6 vacuum casting machines as of December 31, 2022, respectively.
Gross profit. Gross profit increased € 16.4 million from € 128.8 million in the year ended December 31, 2022, to € 145.1 million in the year ended December 31, 2023, mainly driven by increased revenue in all three Materialise segments, slightly offset by higher production costs. The overall gross profit margin (gross profit divided by our revenue) amounted to 56.7% in the year ended December 31, 2023, compared to 55.5% in the year ended December 31, 2022.
Research and development, or R&D, sales and marketing, or S&M, and general and administrative, or G&A, expenses. R&D, S&M and G&A expenses decreased, in the aggregate, to € 133.0 million in the year ended December 31, 2023, compared to € 134.8 million in the year ended December 31, 2022. R&D expenses increased from € 37.6 million to € 38.1 million, or 1.4%. S&M expenses decreased from € 62.1 million to € 57.8 million, or 6.9%, driven by our Materialise Software segment sales reorganization. G&A expenses increased from € 35.1 million to € 37.1 million, or 5.5%. The G&A expenses included the roll-out of our ongoing internal digital transformation project.
Net other operating income. Net other operating income decreased to a negative € 6.5 million, in the year ended December 31, 2023, compared to a positive € 3.2 million net other operating income in the year ended December 31, 2022. The main drivers of this decrease were an arbitration settlement of € 5.2 million, an impairment loss related to intangible assets of € 3.0 million, an impairment loss related to goodwill of € 1.2 million, and an amortization expenses of acquired intangible assets, which represented an expense of € 4.0 million for the year ended December 31, 2023, compared to € 5.1 million for the year ended December 31, 2022. These expenses were partially offset by withholding tax exemptions (€ 3.0 million), grants received (€ 1.8 million), and R&D tax credits (€ 1.4 million).
Net financial income (financial income and financial expense). Net financial income was € 1.2 million in the year ended December 31, 2023, compared to a net income of € 1.7 million in the year ended December 31, 2022. In 2023, the net positive result was mainly due to increased interest income on short-term deposits from higher prevailing interest rates, partially offset by increased interest expense on our loans and borrowings.
Income taxes. Income taxes in the year ended December 31, 2023 resulted in an expense of € 0.1 million, which was a combination of deferred tax benefits amounting to € 2.3 million and current income tax expenses of € 2.4 million.
Net profit/loss. As a result of the factors described above, net profit amounted to € 6.7 million in the year ended December 31, 2023 compared to a net loss of € 2.2 million in the year ended December 31, 2022.
4
Final version – Free translation for information purposes only
EBITDA. As a result of the factors described above, our consolidated EBITDA was € 27.1 million in the year ended December 31, 2023, compared to € 19.2 million in the year ended December 31, 2022, an increase of € 8.0 million. During 2023, we continued to strategically invest in our growth businesses and progressed on our transition to cloud-based annual license revenue in our Materialise Software segment. In 2023, revenue increased by 10.4%. Our 2023 EBITDA included expenses of € 4.2 million from the impairment of goodwill (€ 1.2 million) and partial impairment of the intangible assets (€ 2.4 million) of Materialise Motion NV and the impairment of intangible and tangible assets (€ 0.7 million) of Engimplan. These expenses were, among others, not reflected in our Adjusted EBITDA. Our consolidated Adjusted EBITDA was € 31.4 million in the year ended December 31, 2023, compared to € 19.0 million in the year ended December 31, 2022, an increase of € 12.4 million.
Our Materialise Software segment’s Adjusted EBITDA was € 7.5 million in the year ended December 31, 2023, compared to € 1.5 million in the year ended December 31, 2022. This segment’s Adjusted EBITDA margin (the segment’s Adjusted EBITDA divided by the segment’s revenue) increased to 16.8% in the year ended December 31, 2023, from 3.5% for the year ended December 31, 2022. The increase in the Adjusted EBITDA margin was the result of costs containment efforts while further investing in R&D expenses.
Our Materialise Medical segment’s Adjusted EBITDA amounted to € 26.5 million in the year ended December 31, 2023, compared to € 18.8 million in the year ended December 31, 2022. The segment’s Adjusted EBITDA margin increased to 26.2% in the year ended December 31, 2022 from 22.2% in the year ended December 31, 2022. The increase in the segment’s Adjusted EBITDA margin was as a result of increased revenues while keeping costs under control.
Our Materialise Manufacturing segment’s Adjusted EBITDA amounts to € 7.5 million in the year ended December 31, 2023, from € 8.2 million in the year ended December 31, 2022. The Adjusted EBITDA margin of this segment decreased to 6.8% in the year ended December 31, 2023, from 8.0% in the year ended December 31, 2022, as a result of less favorable market conditions and continued investments in our growth business lines.
The total balance sheet amounted to € 396.6 million in the year ended December 31, 2023, compared to € 411.3 million in the year ended December 31, 2022.
Non-current assets decreased € 4.6 million from € 194.8 to € 190.2 million in the year ended December 31, 2023. Our goodwill decreased by € 1.0 million. Our intangible assets, property, plant & equipment and right-of-use assets decreased by € 5.6 million to € 135.0 million. Our other non-current assets amount to € 5.5 million.
Our cash and cash equivalents decreased with € 13.3 million to € 127.6 million per December 31, 2023.
Our loans & borrowings decreased € 16.5 million to € 56.5 million per December 31, 2023. Of the total debt, € 22.9 million is short term.
Total equity per December 31, 2023 amounts to € 236.6 million compared to € 228.9 million last year.
5
Final version – Free translation for information purposes only
| 2. | Analysis of the operating results at the level of the company |
At the level of the Company, the results of our operations, as derived from our statutory annual accounts prepared in accordance with Belgian GAAP, can be summarized as follows:
Comparison of the Years Ended December 31, 2023 and 2022
| Year Ended December 31, | ||||||||||||
| 2023 | 2022 | % Change | ||||||||||
| (in thousands of €) | (%) | |||||||||||
| Operating income | 192,842 | 172,796 | 11.6 | % | ||||||||
| 70 Turnover | 162,690 | 139,864 | 16.3 | % | ||||||||
| 71 Stocks of finished goods and WIP increase | 556 | 229 | 143.1 | % | ||||||||
| 72 Own work capitalized | 23,213 | 26,352 | -11.9 | % | ||||||||
| 74 Other operating income | 5,924 | 6,291 | -5.8 | % | ||||||||
| 76 Non-recurring operating income | 459 | 60 | 661.5 | % | ||||||||
| Operating charges | 188,291 | 181,008 | 4.0 | % | ||||||||
| 60 Raw materials-consumables | 37,657 | 33,927 | 11.0 | % | ||||||||
| 61 Services and other goods | 57,137 | 61,741 | -7.5 | % | ||||||||
| 62 Remuneration, social security and pensions | 55,375 | 50,919 | 8.8 | % | ||||||||
| 63 Depreciations and other amounts written off | 32,377 | 33,429 | -3.1 | % | ||||||||
| 64 Other operating charges | 5,740 | 690 | 731.5 | % | ||||||||
| 66 Non-recurring operating charges | 6 | 303 | ||||||||||
| Operating profit (loss) | 4,551 | -8,212 | -155.4 | % | ||||||||
| Financial income | 10,782 | 14,568 | ||||||||||
| Financial charges | 11,569 | 7,001 | ||||||||||
| Gain (loss) on ordinary activities before taxes | 3,764 | -645 | ||||||||||
| Transfer from deferred taxes and tax free reserves | 1 | 1.49 | ||||||||||
| Taxes on result | 207 | 229 | ||||||||||
| Net profit | 3,558 | -872 | ||||||||||
| Year Ended December 31, | ||||||||
| 2023 | 2022 | |||||||
| (in thousands of €) | ||||||||
| Assets | 375,993 | 392,108 | ||||||
| Formation expenses | 2,355 | 3,329 | ||||||
| Fixed assets | 169,413 | 180,284 | ||||||
| Current assets | 204,225 | 208,495 | ||||||
| Equity and Liabilities | 375,993 | 392,108 | ||||||
| Equity | 235,975 | 232,419 | ||||||
| Provisions and deferred taxes | 483 | 193 | ||||||
| Amounts payable | 139,535 | 159,496 | ||||||
6
Final version – Free translation for information purposes only
Analysis
The evolution of the operations of the Company is in line with the operations of the Group. Reference is made to Section 1 of this report in this respect.
Operating income was €192.8 million in the year ended December 31, 2023 compared to €172.8 million in the year ended December 31, 2022, an increase of €20.0 million, or 11.6%.
Operating charges amounted to €188.3 million in the year ended December 31, 2023, compared to €181.0 million in the year ended December 31, 2022. This increase of 4.0% was mainly due to:
| - | higher purchases of raw materials & consumables of €3.7 million; | |
| - | lower purchases of services & other goods of €4.6 million; | |
| - | a remuneration cost increase of €4.5 million or 8.8%; | |
| - | depreciation and provisions decreased €1.0 million to €32.4 million and includes 100% depreciation of development expenses of €22.4 million that were activated in 2023, allowing the company to keep benefiting from tax credits. |
As a result, the operating result in 2023 amounted to €4.6 million, compared to -€8.2 million in 2022.
Financial income amounted to €10.8 million in 2023, compared to €14.6 million in 2022 and included dividends of €1.4 million received from subsidiaries.
Financial charges amounted to €11.6 million in the year ended December 31, 2022, compared to €7.0 million in the year ended December 31, 2022. The 2023 financial charges included an impairment of €7.25 million of the participation in Materialise Motion NV.
In 2023 there is a net profit of €3.6 million, compared to a net loss of €0.9 million last year.
The total balance sheet amounted to €376.0 million in the year ended December 31, 2023, compared to €392.1 million in the year ended December 31, 2022.
Fixed assets net book value decreased €10.9 million to €169.4 million in the year ended December 31, 2023. Our participating interests decreased with €7.2 million to €41.1 million as a result of an impairment posted on the Materialise Motion NV participation.
Our other long term receivables of €4.2 million per December 31, 2023 included a convertible loan to Fluidda NV of €3.7 million.
Our cash at bank decreased €6.3 million to €109.6 million per December 31, 2023.
Our financial debt decreased €14.6 million to €53.1 million per December 31, 2022 of which €20.9 million is related to short term debt.
Total equity per December 31, 2023 amounts to €236.0 million compared to €232.4 million last year. This increase is the result of the incorporation of the net result of the year of €3.6 million.
Based on the positive operating result of the year, we maintain our valuation rules in the company based on going concern. Such presumption is justified by the Company’s strong equity position of €236.0 million per December 31, 2023 and the outcome of the sensitivity testing that we have performed on our projected income statements and bank covenants.
Appropriation of profit
The net profit for 2023, to be appropriated, amounted to €3,561,649.
7
Final version – Free translation for information purposes only
Together with the loss carried forward from previous financial years €12,338,497, we propose the total amount to be appropriated of €8,776,848 to be carried forward in its entirety.
| 3. | Structure and development of the group |
On December 31, 2023, Materialise NV had the following (direct and indirect) subsidiaries:
| Name | Jurisdiction of Incorporation | |
| Materialise SAS | France | |
| Materialise GmbH | Germany | |
| Materialise Japan K.K. | Japan | |
| Materialise s.r.o | The Czech Republic | |
| Materialise USA, LLC | United States | |
| OBL SAS | France | |
| Materialise Austria GmbH | Austria | |
| Materialise SDN. Bhd. | Malaysia | |
| Materialise Ukraine LLC | Ukraine | |
| RapidFit NV | Belgium | |
| Materialise SA | Poland | |
| Meridian Technique Limited | United Kingdom | |
| OrthoView Holdings Limited | United Kingdom | |
| Materialise Colombia SAS | Colombia | |
| Materialise Motion NV | Belgium | |
| Materialise Shanghai Co. Ltd. | China | |
| Materialise Australia PTY Ltd | Australia | |
| Materialise S.R.L. | Italy | |
| ACTech Holding GmbH | Germany | |
| ACTech GmbH | Germany | |
| ACTech North America Inc. | United States | |
| Engimplan Engenharia de Implante Industria E Comércio Ltda. | Brazil | |
| Engimplan Holding Ltda. | Brazil | |
| Materialise Limited | South Korea | |
| Tianjin Zhenyuan Materialise Medical Technology Ltd | China |
Materialise also has representative offices in Spain, and in Hungary.
On April 9, 2021, we acquired an option to buy Link3D Inc., which we exercised on November 15, 2021. We closed the acquisition on January 4, 2022. This acquisition was effected by our U.S. subsidiary, Materialise USA, LLC, by exercising the call option. As a result of this transaction, Materialise USA became the sole shareholder of Link3D, and subsequently Link3D was merged into Materialise USA. Link3D was an additive workflow and digital manufacturing software company. The acquisition of Link3D is intended to strengthen and accelerate the creation of the Materialise software platform.
On September 1, 2022, we acquired Identify3D, a company that develops software to encrypt, distribute and trace the flow of digital parts across complex supply chains. This acquisition was effected by our U.S. subsidiary, Materialise USA, LLC, and subsequently Identify3D was merged into Materialise USA. The acquisition of Identify3D is intended to strengthen the security features of our CO-AM platform.
8
Final version – Free translation for information purposes only
| 4. | Material events since the end of the financial year |
No material events.
| 5. | Risks and uncertainties |
The risks and uncertainties with which both the Group and the Company are faced, can be summarized as follows. For a more detailed explanation of these risks, please refer to the 20-F related to fiscal year 2023. However, other than those risks and uncertainties, we are not aware of any circumstances that are likely to have a material influence on the development of the Company.
| - | We may not be able to maintain or increase the market share or reputation of our software and other products and services that they need to remain or become a market standard. |
| - | We may not be successful in continuing to enhance and adapt our software, products and services in line with developments in market technologies and demands. |
| - | The research and development programs that we are currently engaged in, or that we may establish in the future, may not be successful and our significant investments in these programs may be lost. |
| - | Existing and increased competition may reduce our revenue and profits. |
| - | We rely on collaborations with users of our additive manufacturing and related solutions to be present in certain large-scale markets and, indirectly, to expand into potentially high-growth specialty markets. Our inability to continue to develop or maintain these relationships in the future could harm our ability to remain competitive in existing markets and expand into other markets. |
| - | Our revenue and results of operations may fluctuate. |
| - | Inflation has had and may continue to have an adverse effect on our results. |
| - | Demand for additive manufacturing generally and our additive manufacturing software solutions, products and services in particular may not increase adequately, or at all. |
| - | We are dependent upon sales to certain industries. |
| - | If our relationships with suppliers, including with limited source suppliers of consumables, were to terminate or our manufacturing arrangements were to be disrupted, our business could be adversely affected. |
| - | The dominant software subscription model in the industrial sector is changing, and we may not be successful in developing and deploying a cloud-based platform to offer our software. |
| - | We may not be able to successfully adapt our software offering to the changing needs of the additive manufacturing market. |
9
Final version – Free translation for information purposes only
| - | We depend on the knowledge and skills of key personnel throughout our entire organization, and if we are unable to retain and motivate them or recruit additional qualified personnel, our operations could suffer. |
| - | We may need to raise additional capital from time to time in order to meet our growth strategy and may be unable to do so on attractive terms, or at all. |
| - | As a result of the armed conflict in Ukraine, our supporting operations in Kyiv are expected to continue to be subject to continuous reorganization, uncertainty and instability. |
| - | Our international operations pose currency risks, which may adversely affect our results of operations and net income. |
| - | Our international operations subject us to various risks, and our failure to manage these risks could adversely affect our results of operations. |
| - | We may engage in acquisitions or investments that could disrupt our business, cause dilution to our shareholders and harm our financial condition and results of operations. |
| - | We may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships with third parties that may not result in the development of commercially viable products or the generation of significant future revenue. |
| - | Failure to comply with applicable anti-corruption and trade sanctions legislation could result in fines, criminal penalties and an adverse effect on our business. |
| - | Errors or defects in our software or other products could cause us to incur additional costs, lose revenue and business opportunities, damage our reputation and expose us to potential liability. |
| - | We rely on our information technology systems to manage numerous aspects of our business and customer and supplier relationships, and a disruption of these systems could adversely affect our results of operations. |
| - | A breach of security in our products or computer systems may compromise the integrity of our products, harm our reputation, create additional liability and adversely impact our financial results. |
| - | If our service center operations are disrupted, sales of our 3D printing services, including the medical devices that we print, may be affected, which could have an adverse effect on our results of operations. |
| - | Our failure to adequately address current and emerging sustainability risks, including environmental, social and governance (ESG) matters, could have a material adverse effect on our business, financial condition and results of operations. |
| - | Our medical business, financial condition, results of operations and cash flows could be significantly and negatively affected by substantial government regulations. |
10
Final version – Free translation for information purposes only
| - | Our Materialise Medical segment’s 3D printing operations are required to operate within a quality management system that is compliant with the regulations of various jurisdictions, including the requirements of ISO 13485, and the U.S. Quality System Regulation, which is costly and could subject us to enforcement action. |
| - | If we are unable to obtain patent protection for our products or otherwise protect our intellectual property rights, our business could suffer. |
| - | We do not expect to be a passive foreign investment company for U.S. federal income tax purposes; however, there is a risk that we may be classified as a passive foreign investment company, which could result in materially adverse U.S. federal income tax consequences to U.S. investors. |
| - | We may not be able to maintain or increase the market share or reputation of our software and other products and services that they need to remain or become a market standard. |
| 6. | Research and development |
We have an ongoing research and development program to improve and expand the capabilities of our existing technology portfolio, which reflects our continued investments in a range of disciplines, including software development, industrial, and mechanical and biomedical engineering.
We have a long history of research and development through collaborations, which augment our internal development efforts. As of December 31, 2023, we were active in over 20 government funded research projects and we also employed multiple researchers with a publicly funded scholarship. With our platform technologies and strong track record in successful commercialization of scientific innovations, we receive many requests for participation in new development projects. While we strongly protect our intellectual property in our core competencies, many of our products require collaborations in order to create healthy ecosystems for their successful implementation.
As of December 31, 2023, we had more than 50 active research and development projects in various stages of completion and approximately 540 FTEs and fully dedicated consultants working on research and development in our facilities in Belgium, France, Germany, Spain, the United Kingdom, the United States, Colombia, Ukraine and Malaysia.
We also regularly apply for research and development grants and subsidies under, among other, European, Belgian, British, French and German, grant rules. The majority of these grants and subsidies are non-refundable. We have received grants and subsidies from different authorities, including the Flemish government (VLAIO, or Vlaams Agentschap Innoveren en Ondernemen), the European Union (FP7 and H2020 framework programs) and BMBF, the German Federal Ministry of Education and Research.
We expect to continue to invest significantly in research and development in the future.
11
Final version – Free translation for information purposes only
| 7. | Financial instruments |
The Company has used interest rate and foreign currency swaps as financial instruments in the course of the financial period. More detailed information is included in note 25 of our annual report on Form 20-F.
| 8. | Miscellaneous |
| 8.1 | Internal audit and risk management |
Our management, including our Chief Executive Officer and our Chief Financial Officer, has concluded that our internal control over financial reporting was effective as of December 31, 2023.
We further refer to Item 15 included in our annual report on Form 20-F which has been filed with the SEC and is available on our website.
| 8.2 | Authorized capital |
By resolution of the extraordinary shareholders' meeting of April 23, 2014, which entered into force on June 30, 2014, our shareholders authorized the board of directors, for a period of five years from August 18, 2014, to increase the Company's share capital, in one or more transactions, up to a maximum amount of €2,714,634.83 (the so-called authorised capital).
More recently (and replacing the previous resolution), by resolution of our extraordinary shareholders’ meeting of November 5, 2020, which entered into force on November 9, 2020, our shareholders authorized our board of directors, for a period of five years from November 9, 2020, to increase our share capital, in one or more transactions (including through the issuance of warrants), up to a maximum amount of €4,067,700.72 (the so-called authorised capital).
On June 9, 2021, the board of directors of the Company decided to increase the share capital of Materialise, which capital increase was confirmed on June 14, 2021 and July 6, 2021, by €320,000.00 (excluding an issuance premium of €78,484,793.95) and €48,000.00 (excluding an issuance premium of €11,772,719.09), respectively, against the issuance of 4,000,000 and 600,000 new ordinary shares, respectively. As such, the Company’s share capital was increased from €4,096,520.81 to €4,464,520.81, represented by 58,770,607 shares.
On the 28th of December 2022, the board of directors of the Company decided to increase the share capital of Materialise, after which the share capital became €4,487,050.49 represented by 59.067.186 shares.
In the context of the abovementioned capital increases, the board of directors decided to exclude the preferential subscription right of existing shareholders. The board of directors believed that doing so would allow the Company to (i) promptly respond to an opportunity in the financial markets and thus to (ii) efficiently acquire additional financial means that would ensure the further growth of the Company. As such, the board of directors concluded that excluding the preferential subscription right of existing shareholders was in the interest of the Company.
| 8.3 | Acquisition or disposal of own shares |
Not applicable.
12
| 8.4 | Conflicts of interest |
There have not been any disclosures of conflict of interest as provided by the Belgian Code of Companies and Associations
[Signature Page Follows]
13
Final version – Free translation for information purposes only
Done in Leuven on May 14, 2024
| /s/ Wilfried Vancraen | /s/ Peter Leys | |
|
Wilfried Vancraen |
Peter Leys | |
| Director | Director |
14